Instructions: Print this exam worksheet. Return to the course page using the link below. Read the course material. Enter your answers on this worksheet. Return to the course page and click the link 'Take Test.' Transfer your answers.
https://www.quantumunitsed.com/go/2129
1. Proper use, adaptation, modifications, or decisions to disregard the guidelines, in whole or in part, are entirely the responsibility of the clinician who uses the guidelines.
A. True
B. False
2. All of the following pertain to antipsychotics, except for:
A. The risks are insignificant.
B. There is no difference in efficacy between first generation antipsychotics and second generation antipsychotics.
C. First and second generation antipsychotics are heterogeneous within the class and differ in many properties, such as efficacy, side-effects, and pharmacology.
D. Antipsychotics carry extrapyramidal symptoms liability and metabolic effects.
3. A proper antipsychotic trial sequence begins with systematic _____ week trial of one antipsychotic with optimal dosing.
A. 4 to 6
B. 6 to 10
C. 8 to 12
D. 12 to 16
4. The primary goal of bipolar disorder depression care is:
A. Remission
B. Prevention of relapse
C. Full functional recovery
D. All of the above
5. Which of the following has established efficacy for bipolar II disorder?
A. Quetiapine
B. Lurasidone
C. Both (A) and (B)
D. None of the above
6. All of the following are primary goals of bipolar disorder mania care, except for:
A. Safety
B. Symptomatic improvement
C. Maintenance of response
D. Patient psychoeducation
7. Caution should be used when prescribing divalproex to women of reproductive age due to increased risk in pregnant women of neural tube defects and other major birth defects.
A. True
B. False
8. For many individuals with bipolar disorder, the illness is:
A. Highly relapse-prone
B. Chronic in nature
C. Lifelong
D. All of the above
9. Vigilance for bipolar disorder is warranted among individuals presenting in healthcare settings with manic symptoms, as manic episodes are often “polarity-first” as well as “polarity-predominant” in individuals with bipolar disorder.
A. True
B. False
10. Replicated evidence indicates that _____ is insufficiently efficacious in adults with bipolar depression.
A. Olanzapine
B. Armodafinil
C. Fluoxetine
D. Quetiapine
11. Data has recently emerged indicating that electroconvulsive therapy is superior to pharmacotherapy in treatment-resistant bipolar depression.
A. True
B. False
12. For many individuals with depression, cognitive dysfunction may be a consequence of:
A. Illness severity
B. Psychiatric comorbidity
C. Medical comorbidity
D. Any of the above
13. Within the neuromodulatory category, the most compelling evidence is for:
A. Repeated transcranial magnetic stimulation
B. Magnetic seizure therapy
C. Electroconvulsive therapy
D. Transcranial direct-current stimulation
14. Evidence for disparate formulations of _____, provides evidence of efficacy for both depression and suicidality measure in treatment-resistant depression populations.
A. Anti-inflammatory agents
B. Ketamine
C. Antioxidants
D. Nutraceuticals
15. Initial treatment of schizophrenia should include monotherapy with an oral second generation antipsychotic other than:
A. Clozapine
B. Risperidone
C. Olanzapine
D. Quetiapine
16. All antipsychotics are effective in reducing negative and cognitive symptoms which significantly contribute to the disability associated with schizophrenia, and minimally effective for positive symptoms.
A. True
B. False
17. Response over the first _____ of antipsychotic therapy is highly predictive of long-term response.
A. 12 weeks
B. 4 to 6 weeks
C. 2 to 4 weeks
D. Week
18. Which of the following is a principle of pharmacotherapy during pregnancy?
A. Prioritize medications that have worked for the mother in the past.
B. Minimize polypharmacy, if possible, as multiple exposures may increase risks to the fetus.
C. If the patient has psychotic symptoms, antipsychotic medications are the most effective treatment and have no confirmed increase in birth defects.
D. All of the above.
Copyright © 2025 Quantum Units Education
Visit us at QuantumUnitsEd.com!